TICKERNERD
Menu
UPBUPBHealthcare · Biotechnology

UPB Stock Forecast: Upstream Bio, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$5.81
+1.40% on the day

The 7 Wall Street analysts covering Upstream Bio, Inc. hold a median 12-month price target of $25 — +330.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 14 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$313.3M
Ticker Nerd rank
27 / 100
Median analyst target
$25
Analysts covering
7
Revenue$773K−17.5% y/y
Operating income−$42.4M
Net income−$39.7M
Free cash flow−$35.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−17.8%
YTD
−78.6%
1Y
−66.9%
From 52W high
−82.2%
From 52W low
+1.4%
$6
$33
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UPB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Upstream Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
73
Size
61
Revisions
51
Issuance
41
Quality
41
Value
32
Volatility
29
Growth
23
Momentum
18

Accruals (73): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UPB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UPB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26UPBHigh $75Median $25Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $9Median $25High $75

The green dot is the last close — the median target sits +330.3% from it.

Recent analyst actionsNewest first

Of the 18 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
2 Sept 2026HC Wainwright & Co.ReiteratesBuy$36
14 Aug 2026JP MorganMaintainsNeutral—
14 Aug 2026JP MorganMaintainsNeutral$8.00 → $9.00
12 Aug 2026Truist SecuritiesMaintainsBuy—
12 Aug 2026Truist SecuritiesMaintainsBuy$43 → $25
12 June 2026JP MorganDowngradeNeutral$35 → $8.00
12 June 2026JP MorganDowngradeNeutral—
3 June 2026HC Wainwright & Co.InitiatesBuy—
14 May 2026MizuhoMaintainsOutperform—
27 Mar 2026Evercore ISI GroupDowngradeIn-Line—
18 Dec 2025MizuhoInitiatesOutperform—
2 Dec 2025LifeSci CapitalInitiatesOutperform—
18 Nov 2025Evercore ISI GroupInitiatesOutperform—
14 Oct 2025Truist SecuritiesInitiatesBuy—
5 Nov 2024JP MorganInitiatesOverweight—
5 Nov 2024Piper SandlerInitiatesOverweight—
5 Nov 2024TD CowenInitiatesBuy—
5 Nov 2024William BlairInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UPB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

UPB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Upstream Bio, Inc. returned −66.9% against +17.0% for the S&P 500, dividends included.

UPB vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26UPBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UPB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
3
Fundamentals

Upstream Bio, Inc. (UPB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 86% of US stocks

Price / sales
100.9×

Cheaper than 4% of US stocks

Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
−0.3×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−17.5%

Higher than 12% of US stocks

Earnings growth (YoY)
−17.5%

Higher than 22% of US stocks

Gross margin
—
Operating margin
−5481.0%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−46.1%

Higher than 22% of US stocks

Return on assets
−30.3%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Upstream Bio, Inc. (UPB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Upstream Bio, Inc. has a market value of $313.3M and an enterprise value of $53.5M.

  • Revenue in the twelve months to 30 June 2026: $3.2M. The latest quarter shrank 17.5% year on year.

  • Net income over the same four quarters: −$156.5M, a −4955.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.88.

  • Free cash flow in the twelve months to 30 June 2026: −$136.5M.

  • Shares outstanding: 54.8M.

  • Trailing P/E: −2.2×; forward P/E: −2.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Upstream Bio, Inc. employs 75 people — $42K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

UPB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
UPBUpstream Bio, Inc.$313.3M
27
AGENAgenus, Inc.$319.1M
89
SABSSAB Biotherapeutics, Inc.$314.8M
36
IFRXInflaRx NV$312.3M
9
QTTBQ32 Bio, Inc.$324.7M
82
ABEOAbeona Therapeutics, Inc.$309.8M
41
LXEOLexeo Therapeutics, Inc.$330.6M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Upstream Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UPB news & analysis

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

GlobeNewsWire · 8 Sept 2026positive

Upstream Bio presented Phase 2 VALIANT trial results for verekitug in severe asthma at the ERS Congress 2026, reporting a 56% reduction in annualized asthma exacerbation rate versus placebo with 100 mg dosed every 12 weeks, along with improvements in lung function and exhaled nitric oxide. The company said it remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027.

Why it matters — The VALIANT data supports verekitug's efficacy and progress toward Phase 3 development, a key catalyst for Upstream Bio's pipeline.

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

GlobeNewsWire · 1 Sept 2026positive

Upstream Bio announced pivotal Phase 3 development plans for verekitug in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), following productive FDA discussions. The company will study a 400 mg dose administered every 12 weeks versus placebo, with one pivotal Phase 3 trial per indication, and remains on track to initiate both trials in Q1 2027.

Why it matters — The announcement clarifies the company's Phase 3 development pathway for its lead candidate, verekitug, across two severe respiratory indications, which is a key milestone for the clinical-stage company.

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 11 Aug 2026positive

Upstream Bio, Inc. (UPB) reported a Q2 loss of $0.73 per share, narrower than the Zacks Consensus Estimate of a $0.78 loss, and slightly improved from the $0.74 per share loss reported a year ago.

Why it matters — The smaller-than-expected quarterly loss may signal better-than-anticipated cost management or operational progress for UPB.

FAQ

Frequently asked questions about UPB stock

What is the UPB stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Upstream Bio, Inc. have a median 12-month price target of $25, with estimates ranging from $9 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is UPB stock a buy right now?

Of the 7 analysts covering Upstream Bio, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Upstream Bio, Inc. 27 out of 100 across roughly 4,600 US stocks as at 14 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank UPB?

As at 14 Sept 2026, Upstream Bio, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (73 of 100).

Will UPB stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +330.3% from the last close, and Ticker Nerd's factor model ranks Upstream Bio, Inc. 27 out of 100 as at 14 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the UPB stock forecast for 2030?

No analyst covering Upstream Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UPB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $75 over the next 12 months.

How has UPB stock performed over the past year?

Upstream Bio, Inc. returned -66.9% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Upstream Bio, Inc. do?

Upstream Bio, Inc. Common Stock represents an equity interest in Upstream Bio, a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, with an initial emphasis on severe respiratory disorders.

What is the latest news on UPB?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026". Upstream Bio presented Phase 2 VALIANT trial results for verekitug in severe asthma at the ERS Congress 2026, reporting a 56% reduction in annualized asthma exacerbation rate versus placebo with 100 mg dosed every 12 weeks, along with improvements in lung function and exhaled nitric oxide. The company said it remains on track to initiate Phase 3 trials in severe asthma and CRSwNP in Q1 2027.

Company

About Upstream Bio, Inc.

Upstream Bio, Inc. Common Stock represents an equity interest in Upstream Bio, a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, with an initial emphasis on severe respiratory disorders. The company’s lead program, verekitug, is being studied for conditions such as severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio is centered on advancing antibody-based therapies that target pathways involved in immune and inflammatory responses, positioning the company within the broader biotechnology sector. Headquartered in Waltham, Massachusetts, Upstream Bio operates as a pre-commercial developer of drug candidates, with its current business concentrated on research, clinical development, and the advancement of its respiratory disease pipeline.

CEO Dr. E. Rand Sutherland M.D., M.P.H. · 75 employees · United States · https://upstreambio.com